Accelerate Diagnostics Inc (NASDAQ:AXDX) Investor Investigation Over Potential Securities Laws Violations Announced

If you purchased shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Accelerate Diagnostics
Affected Securities: 
NASDAQ: AXDX

March 13, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Accelerate Diagnostics Inc (NASDAQ:AXDX) shares over potential securities laws violations by Accelerate Diagnostics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Accelerate Diagnostics Inc (NASDAQ:AXDX) concerning whether Accelerate Diagnostics may have issued materially misleading business information to the investing public.

Accelerate Diagnostics Inc reported that its Net Loss increased from $15.28 million in 2013 to $30.93 million in 2014. Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) grew from under $1 per share in April 2012 to as high as $30.08 per share in June 2014, respectively $28.78 per share in October 2014.

On February 18, 2015, an article was published that asserted that Accelerate Diagnostics Inc falsely claimed that it had developed a technique for diagnosing pathogens in a blood sample without a need for using a blood culture, while in reality, the test required a blood culture, a fact that significantly reduced the value of the technology. Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX0 declined to as low as $17.29 per share on February 23, 2015.